

HEALTHY U CHIP

PRIOR AUTHORIZATION REQUEST FORM

ACNE VULGARIS AND ROSACEA

Aczone®, Akliel®, Epiduo® Forte, Fabior®, Mirvaso®, Rhofade®, Soolantra®, Tazorac®

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Please note the following do not require prior authorization: adapalene, azelaic acid, topical antibiotics, topical benzoyl peroxide, topical metronidazole, topical retinoids

Product being requested: Aczone® (dapsone), Akliel® (trifarotene), Epiduo® Forte (adapalene/benzoyl peroxide), Fabior® (tazarotene), Mirvaso® (brimonidine), Rhofade® (oxymetazoline), Soolantra® (ivermectin), Tazorac® (tazarotene)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
ACZONE® or AKLIEF® or EPIDUO® FORTE or FABIOR® or TAZORAC®			
1. Does the member have a diagnosis of acne vulgaris?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Does documentation show that the member has tried and failed ALL of the following categories: <ul style="list-style-type: none"> • topical benzoyl peroxide • topical or oral antibiotic (e.g. clindamycin, sulfacetamide, erythromycin) • topical retinoid (e.g. adapalene, tretinoin, tazarotene) • Topical generic dapsone or tazarotene 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
MIRVASO® or RHOFADÉ® or SOOLANTA®			
1. Does the member have a diagnosis of rosacea?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Does documentation show that the member has failed a trial of a topical metronidazole agent?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Does documentation show that the member has failed a trial of a topical generic azelaic acid?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

4. Soolantra® is the preferred product. If Rhofade® or Mirvaso® is being requested, has Soolantra® been trialed and failed first?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member's therapy been re-evaluated within the past 12 months?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Does the member show a continued medical need for the therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician's Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM-CHIP-001
 Origination Date: 07/01/2024
 Reviewed/Revised Date:
 Next Review Date:
 Current Effective Date: 07/01/2024

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.